H. Tran

发表

Chemopreventive effects of deguelin, a novel Akt inhibitor, on tobacco-induced lung tumorigenesis.

R. Price, W. Hong, D. Cody, 2005, Journal of the National Cancer Institute.

The BATTLE trial: personalizing therapy for lung cancer.

Edward S. Kim, S. Lippman, F. Khuri, 2011, Cancer discovery.

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Michael Peyton, John D. Minna, Li Shen, 2012, Clinical Cancer Research.

Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial

Michael Peyton, John D. Minna, Lixia Diao, 2013, Clinical Cancer Research.

Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment

P. A. Futreal, Xin Hu, I. Wistuba, 2020, Clinical Cancer Research.

Estrogen promotes resistance to bevacizumab in murine models of non-small cell lung cancer.

Jing Wang, J. Minna, I. Wistuba, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.

T. Dang, R. Herbst, D. Carbone, 2010, Lung cancer.

Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer.

F. Khuri, W. Hong, R. Herbst, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of secreted proteins that mediate cell-cell interactions in an in vitro model of the lung cancer microenvironment.

A. Pandey, C. Creighton, R. Chaerkady, 2008, Cancer research.

Phase II Trials of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma

W. Hong, I. Wistuba, J. Lee, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.

Diane D. Liu, W. Hong, I. Wistuba, 2014, Clinical lung cancer.

A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy.

P. Kantoff, E. Heath, M. Carducci, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.

R. Herbst, D. Carbone, S. Solomon, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

COPD-Type lung inflammation promotes K-ras mutant lung cancer through epithelial HIF-1α mediated tumor angiogenesis and proliferation

H. Tran, M. Caetano, E. Ostrin, 2018, Oncotarget.

Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma

E. Jonasch, J. Heymach, H. Tran, 2009, Cancer.

Serum Signature of Hypoxia-Regulated Factors Is Associated with Progression after Induction Therapy in Head and Neck Squamous Cell Cancer

K. Ang, S. Lippman, W. Hong, 2010, Molecular Cancer Therapeutics.

A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer.

I. Wistuba, J. Lee, J. Erasmus, 2014, The oncologist.

Phase I Study of the Farnesyltransferase Inhibitor BMS-214662 Given Weekly in Patients with Solid Tumors

Edward S. Kim, F. Khuri, G. Ayers, 2005, Clinical Cancer Research.

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Xin Li, Roy S Herbst, Hai T Tran, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (Pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer(NSCLC).

R. Herbst, V. Papadimitrakopoulou, H. Tran, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial

Edward S. Kim, S. Lippman, W. Hong, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept

M. Prados, M. Gilbert, M. Mehta, 2011, Clinical Cancer Research.

Novel marine-derived anticancer agents: a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors.

L. Pusztai, J. Abbruzzese, J. Wright, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer.

J. Roth, I. Wistuba, J. Lee, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The use of improved and complete enrichment co-amplification at lower denaturation temperature (ICE COLD-PCR) method for the detection of EGFR and KRAS mutations from cell-free plasma DNA of non-small cell lung cancer (NSCLC) patients.

Edward S. Kim, W. Hong, I. Wistuba, 2014 .

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.

J. Heymach, A. Tsao, L. Byers, 2022, Cancer cell.

Severe loss of adipose tissue in a Vietnamese lipodystrophy patient caused by LMNA p.G465D mutation: a first clinical characterization and two-year follow-up

H. Tran, H. H. Nguyen, Ton Dang Nguyen, 2022, Journal of pediatric endocrinology & metabolism : JPEM.

Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer

Jing Wang, I. Wistuba, J. Fujimoto, 2022, British Journal of Cancer.

Correlative analyses of plasma cytokine/angiogenic factor (C/AF) profile, gender and outcome in a randomized, three-arm, phase II trial of first-line vandetanib (VAN) and/or carboplatin plus paclitaxel (CP) for advanced non-small cell lung cancer (NSCLC)

Edward S. Kim, J. Lee, J. Heymach, 2007 .

Abstract LB-88: Gene expression signatures predictive of clinical outcome and tumor mutations in refractory NSCLC patients (pts) in the BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination)

Edward S. Kim, J. Weinstein, K. Coombes, 2011 .

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

N. Ajami, J. Roth, I. Wistuba, 2021, Nature Medicine.

A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer

G. Hortobagyi, G. Gladish, D. Booser, 2012, Cancer.

A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: Clinical results and biomarker analysis

E. Jonasch, J. Heymach, P. Corn, 2008 .

Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.

E. Estey, S. Zhao, G. Sanchez-Williams, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The KRAS-variant and treatment response in BATTLE-1.

Edward S. Kim, F. Slack, Jun Yu, 2014 .

Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma

V. Papadimitrakopoulou, H. Tran, J. Wright, 2011, Cancer.

Phase I study of oral topotecan in hematological malignancies.

E. Estey, H. Kantarjian, F. Giles, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Prospective evaluation of carboplatin AUC dosing in patients with a BMI ≥27 or Cachexia

M. Riggs, H. Tran, J. Herrington, 2006, Cancer Chemotherapy and Pharmacology.

Circulating baseline plasma cytokines and angiogenic factors (CAF) as markers of tumor burden and therapeutic response in a phase III study of pazopanib for metastatic renal cell carcinoma (mRCC).

J. Heymach, C. Sternberg, H. Tran, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cyclic AMP-Responsive Element Binding Protein– and Nuclear Factor-κB–Regulated CXC Chemokine Gene Expression in Lung Carcinogenesis

Edward S. Kim, Z. Ju, J. Koo, 2008, Cancer Prevention Research.

Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.

B. Andersson, H. Tran, P. Duggan, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study.

B. Andersson, H. Tran, R. Champlin, 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Characterization and identification of specific EGFR mutations in circulating tumor cells (CTCs) isolated from non-small cell lung cancer patients using antibody independent method, ApoStream.

A. Tsao, F. Fossella, V. Papadimitrakopoulou, 2013 .

Lorazepam for seizure prophylaxis during high-dose busulfan administration

H. Tran, S. Koontz, Kw Chan, 2002, Bone Marrow Transplantation.

Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer

Jason M. Johnson, J. Lee, F. Janku, 2022, The oncologist.

KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib

Jing Wang, I. Wistuba, W. Lu, 2015, Clinical Cancer Research.

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.

Edward S. Kim, Diane D. Liu, W. Hong, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis

S. Kopetz, M. Overman, H. Tran, 2011, Clinical Cancer Research.

Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.

P. Thall, B. Andersson, H. Tran, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation.

H. Tran, H. Fernandez, Mark Goodman, 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Hemodynamic Considerations in the Pathophysiology of Peripheral Neuropathy

H. Tran, Daryl I Smith, Joseph K Poku, 2018, Blood Pressure - From Bench to Bed.

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Jing Wang, C. Ren, M. Ha, 2021, Nature.

Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.

R. Herbst, B. Sabloff, K. Pisters, 2004, Lung cancer.

Distinct Biological Roles for the Notch Ligands Jagged-1 and Jagged-2*

J. Minna, L. Girard, C. Creighton, 2009, The Journal of Biological Chemistry.

Plasma Based Protein Signatures Associated with Small Cell Lung Cancer

Jennifer B Dennison, S. Hanash, Jian-Min Yuan, 2021, Cancers.

CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance.

J. Minna, S. Kobayashi, C. Moran, 2023, Cancer cell.

A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components

E. Dmitrovsky, Jing Wang, U. McDermott, 2020, Science Translational Medicine.

Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer: A Phase 2 Clinical Trial

Young Uk Kim, S. H. van der Burg, Jing Wang, 2019, JAMA oncology.

Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer

P. Robson, Jing Wang, J. Roth, 2020, Nature Cancer.

Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma

R. Figlin, H. Tran, A. Zurita, 2017, British Journal of Cancer.

Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer

C. Daniel, S. Kopetz, H. Tran, 2015, Cancer.

Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer

J. Vauthey, S. Kopetz, M. Overman, 2015, British Journal of Cancer.

Neoadjuvant Chemotherapy Increases Cytotoxic T cell, Tissue Resident Memory T cell and B Cell Infiltration in Resectable Non-Small Cell Lung Cancer.

Jing Wang, I. Wistuba, D. Gomez, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma.

I. Wistuba, A. Tsao, H. Tran, 2016, Clinical lung cancer.

Predictive Biomarkers and Personalized Medicine Comprehensive Biomarker Analysis and Final Ef fi cacy Results of Sorafenib in the BATTLE Trial

Edward S. Kim, Jing Wang, J. Minna, 2013 .

Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma

Steven J Frank, John V Heymach, Lucien Nedzi, 2016, Head & neck.

Liposomal Encapsulation of Deguelin: Evidence for Enhanced Antitumor Activity in Tobacco Carcinogen–Induced and Oncogenic K-ras–Induced Lung Tumorigenesis

W. Hong, Ho-Yyoung Lee, J. Woo, 2009, Cancer Prevention Research.

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

P. Jänne, D. Haber, L. Sequist, 2015, Clinical Cancer Research.

Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers

Edward S. Kim, Diane D. Liu, Jing Wang, 2017, Science Translational Medicine.

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.

John V Heymach, Hai T Tran, R. Figlin, 2012, The Lancet. Oncology.

Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer

Jeffrey S. Morris, G. Calin, J. Vauthey, 2019, British Journal of Cancer.

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance.

Jeffrey S. Morris, L. Ellis, S. Kopetz, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-Dose Fenretinide in Oral Leukoplakia

Edward S. Kim, A. Sabichi, S. Lippman, 2009, Cancer Prevention Research.

Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer

Jing Wang, I. Wistuba, J. Fujimoto, 2022, British Journal of Cancer.

Abstract 4745: Circulating cytokine levels predictive of Grade≥3 radiation pneumonitis: Preliminary secondary analysis of a randomized controlled trial of definitive chemoradiation in locally advanced NSCLC

Steven H. Lin, R. Komaki, Z. Liao, 2017 .

Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin.

L. Ellis, K. Hess, C. Bucana, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fenretinide Activity in Retinoid-Resistant Oral Leukoplakia

S. Lippman, F. Khuri, R. Lotan, 2006, Clinical Cancer Research.

Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.

S. Lippman, I. Wistuba, J. Erasmus, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abrogation of Signal Transducer and Activator of Transcription 3 Reactivation after Src Kinase Inhibition Results in Synergistic Antitumor Effects

N. Donato, H. Tran, F. Johnson, 2007, Clinical Cancer Research.

Genotype-specific differences in circulating tumor DNA levels in advanced NSCLC.

Jing Wang, J. Roth, J. Lee, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer

Jing Wang, I. Wistuba, R. Herbst, 2017, Clinical Cancer Research.

Targeted Tissue and Cell‐Free Tumor DNA Sequencing of Advanced Lung Squamous‐Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations

J. Roth, S. Swisher, A. Futreal, 2019, Clinical lung cancer.

Therapeutic Target for Overcoming EGFR Inhibitor Resistance Resistance to EGFR and PI 3 K Inhibitors and Identifies Axl as a Mesenchymal Transition Gene Signature Predicts

Edward S. Kim, J. Weinstein, K. Coombes, 2012 .

Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling

A. Tsao, D. Gibbons, F. Fossella, 2021, JCO precision oncology.

Fludarabine and once-daily intravenous busulfan for allogeneic bone marrow transplantation for Chediak-Higashi syndrome.

H. Tran, L. Worth, C. Mullen, 2003, Journal of pediatric hematology/oncology.

Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.

B. Andersson, H. Tran, T. Madden, 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

B harmacokinetics and Individualized Dose djustment of Intravenous Busulfan in Children with dvanced Hematologic Malignancies Undergoing llogeneic Stem Cell Transplantation

B. Andersson, H. Tran, T. Madden, 2004 .

Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.

J. Lee, H. Tran, L. Ginsberg, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors

R. Herbst, M. Truong, F. Fossella, 2004, Cancer Chemotherapy and Pharmacology.

Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib.

D. Yankelevitz, N. Altorki, H. Tran, 2010, Cancer research.

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.

Edward S. Kim, J. Lee, A. Ryan, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin and gemcitabine combined with herceptin in patients (pt) with her2 overexpressing, untreated, advanced, non-small-cell lung cancer (NSCLC): a phase II trial

F. Khuri, R. Herbst, K. Pisters, 2001 .

Hepatotoxicity with Vismodegib: An MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project

D. West, B. Edwards, D. Raisch, 2017, Drugs in R&D.

Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort

Jing Wang, I. Wistuba, S. Swisher, 2020, Journal for ImmunoTherapy of Cancer.

Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma

P. Tamboli, L. Krug, H. Tran, 2006, Cancer.

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.

E. Jonasch, C. Logothetis, H. Tran, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Immune and circulating tumor DNA profiling following radiation treatment for oligometastatic NSCLC; translational correlatives from a mature randomized phase II trial.

X. Yi, S. Swisher, J. Wargo, 2020, International journal of radiation oncology, biology, physics.

Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors.

J. Abbruzzese, H. Tran, R. Newman, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

1136ONivolumab and ISA 101 HPV vaccine in incurable HPV-16+ cancer

Young Uk Kim, I. Wistuba, J. Lee, 2017 .

Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection.

J. Roth, I. Wistuba, S. Swisher, 2022, Lung cancer.

Phase I and pharmacokinetic study of once-daily dosing of intravenously administered busulfan in the setting of a reduced-intensity preparative regimen and allogeneic hematopoietic stem cell transplantation as immunotherapy for renal cell carcinoma.

H. Tran, M. Pollack, P. Shaughnessy, 2006, Military medicine.

Clinical studies of angiogenesis inhibitors: The university of texas md anderson center trial of human endostatin

R. Herbst, J. Abbruzzese, H. Tran, 2001, Current oncology reports.

The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer

Jeffrey S. Morris, L. Ellis, E. Lin, 2013, PloS one.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Classification by Mass Spectrometry Can Accurately and Reliably Predict Outcome in Patients with Non-small Cell Lung Cancer Treated with Erlotinib-Containing Regimen

T. Dang, P. Massion, R. Herbst, 2009, Journal of Thoracic Oncology.

Phase I study of recombinant human endostatin in patients with advanced solid tumors.

L. Ellis, K. Hess, W. Hong, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Study of Lonafarnib (SCH66336) in Patients With Chemorefractory, Advanced Squamous Cell Carcinoma of the Head and Neck

Edward S. Kim, F. Khuri, W. Hong, 2009, American journal of clinical oncology.

IL-6 mediates suppression of T and NK cells function in EMT-associated TKI-resistant EGFR mutant NSCLC<.

D. Gibbons, H. Tran, X. Le, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Genomic and transcriptomic landscape of oral pre-cancers (OPCs) and risk of oral cancer (OC).

P. A. Futreal, Jing Wang, S. Lippman, 2019, Journal of Clinical Oncology.

MA04.07 Impact of Major Co-Mutations on the Immune Contexture and Response of KRAS-Mutant Lung Adenocarcinoma to Immunotherapy

Jing Wang, I. Wistuba, C. Behrens, 2017 .

Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non–small‐cell Lung Cancer (NSCLC)

J. Roth, D. Gomez, S. Swisher, 2019, Clinical lung cancer.

Analyses of plasma cytokine/angiogenic factors (C/AFs) profile during preoperative treatment with pazopanib (GW786034) in early-stage non-small cell lung cancer

D. Yankelevitz, N. Altorki, S. Swann, 2008 .

MALDI-TOF mass spectrometry proteomic profiling to discriminate response to the combination of bevacizumab and erlotinib in non-small cell lung cancer (NSCLC)

D. D. Billheimer, T. Dang, R. Herbst, 2005 .

Effect of Low-Fat Diets on Plasma Levels of NF-κB–Regulated Inflammatory Cytokines and Angiogenic Factors in Men with Prostate Cancer

M. Dewhirst, K. Do, B. Aggarwal, 2011, Cancer Prevention Research.

Phase I S tudy o f R ecombinant H uman E ndostatin i n Patients W ith A dvanced S olid T umors

L. Ellis, K. Hess, W. Hong, 2002 .

1404 POSTER DISCUSSION Baseline (BL) IL-6, IL-8, and VEGF as Predictive and Prognostic Markers for Overall Survival (OS) in Metastatic Renal Cell Carcinoma (mRCC) Patients (pts) Treated in a Phase III Trial of Pazopanib (PAZO) Versus Placebo (PL)

C. Sternberg, H. Tran, R. Amado, 2011 .

Abstract C18: Epithelial and mesenchymal phenotypic characterization and mutation detection in circulating tumor cells isolated from peripheral blood of non-small cell lung cancer patients with ApoStream® technology

H. Tran, Vishal Gupta, Dave Hasegawa, 2015 .

Plasma cytokines and angiogenic factors (CAFs) associated with risk of recurrence and tumor dependence in patients (pts) with nonmetastatic renal cell carcinoma (RCC).

E. Jonasch, C. Wood, S. Matin, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN).

A. Sabichi, S. Lippman, H. Tran, 2010 .

Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)

Edward S. Kim, R. Herbst, V. Papadimitrakopoulou, 2011, Investigational New Drugs.

A phase 2 study of cetuximab in combination with docetaxel in chemotherapy‐refractory/resistant patients with advanced nonsmall cell lung cancer

Edward S. Kim, Diane D. Liu, R. Herbst, 2009, Cancer.

Algorithmic Guided Screening of Drug Combinations of Arbitrary Size for Activity against Cancer Cells

Li Mao, Paul Damien, Elmira Popova, 2022 .

A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

F. Meric-Bernstam, S. Piha-Paul, A. Tsimberidou, 2023, Cancer Chemotherapy and Pharmacology.

Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively.

Jing Wang, J. Roth, S. Swisher, 2020, Lung cancer.

Inhibition of MMP-13 with modified polymer particles

H. Tran, K. Bratlie, 2016 .

The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer.

L. Ellis, S. Kopetz, M. Overman, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A cytokine and angiogenic factor (CAF) plasma signature for selection of sorafenib (SR) therapy in patients (pts) with metastatic renal cell carcinoma (mRCC).

E. Jonasch, H. Tran, A. Zurita, 2009, Journal of Clinical Oncology.

Phase I trial of imatinib mesylate (IM), cisplatin (P), and irinotecan (I) in small cell lung cancer (SCLC).

P. Tamboli, H. Tran, V. Prieto, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation of specific cytokine profiles with high blood neutrophil-to-lymphocyte ratio and outcome in metastatic colorectal cancer.

Jeffrey S. Morris, J. Vauthey, S. Kopetz, 2012 .

Delayed acute measles inclusion body encephalitis in a 9-year-old girl: ultrastructural, immunohistochemical, and in situ hybridization studies.

H. Tran, S. H. Lee, T. Kim, 1992, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials

R. Figlin, C. Sternberg, H. Tran, 2012 .

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.

E. Jonasch, C. Logothetis, H. Tran, 2012 .

T cell repertoire analysis of non-small cell lung cancer patients treated with neoadjuvant nivolumab alone or in combination with ipilimumab (NEOSTAR trial).

I. Wistuba, S. Swisher, A. Reuben, 2019, Journal of Clinical Oncology.

Abstract A11: Lower baseline levels of plasma hepatocyte growth factor, IL‐6, and IL‐8 are correlated with greater tumor shrinkage in renal cell carcinoma patients treated with pazopanib

R. Figlin, T. Gornet, H. Tran, 2009 .

Plasma cytokine and angiogenic factors (CAFs) predictive of clinical benefit and prognosis in patients (Pts) with advanced or metastatic renal cell cancer (mRCC) treated in phase III trials of pazopanib (PAZO).

C. Sternberg, H. Tran, R. Amado, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MA23.02 Circulating Tumor DNA Analysis with a Novel Variant Classifier for Recurrence Detection in Resected, Early-Stage Lung Cancer

J. Roth, S. Swisher, S. Mortimer, 2018, Journal of Thoracic Oncology.

Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells

P. Damien, G. Mills, S. Lippman, 2009, Molecular Cancer Therapeutics.

Association of circulating cytokine and angiogenic factors (CAFs) with outcomes to second-line FOLFOX plus bevacizumab or cediranib in metastatic colorectal cancer.

S. Kopetz, D. Cunningham, H. Tran, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma.

V. Papadimitrakopoulou, H. Tran, Jack J. Lee, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase II Study of Lonafarnib (SCH66336) in Patients With Chemorefractory, Advanced Squamous Cell Carcinoma of the Head and Neck

Edward S. Kim, F. Khuri, M. Truong, 2009, American journal of clinical oncology.

Liposomal Encapsulation of Deguelin: Evidence for Enhanced Antitumor Activity in Tobacco Carcinogen–Induced and Oncogenic K-ras–Induced Lung Tumorigenesis

Ho-Yyoung Lee, J. Woo, H. Tran, 2009, Cancer Prevention Research.

Auto-reactive antibodies as predictive markers for immune checkpoint–induced pneumonitis.

S. Swisher, Quanzhen Li, H. Tran, 2022, Journal of Clinical Oncology.

Antihyperalgesia effect of AMP-activated protein kinase (AMPK) activators in a mouse model of postoperative pain

H. Tran, Daryl I Smith, 2019, Regional Anesthesia & Pain Medicine.